{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T06:02:28Z","timestamp":1784872948424,"version":"3.55.0"},"reference-count":72,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T00:00:00Z","timestamp":1784851200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T00:00:00Z","timestamp":1784851200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"AstraZeneca GmbH"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cost Eff Resour Alloc"],"DOI":"10.1186\/s12962-026-00803-3","type":"journal-article","created":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T05:08:47Z","timestamp":1784869727000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Cost-effectiveness analysis of molecular reflex testing-based targeted therapy in non-small cell lung cancer from a German healthcare payer perspective using a decision tree model"],"prefix":"10.1186","volume":"24","author":[{"given":"Leonie","family":"Schumacher","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melina Sophie","family":"Kurte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tabea","family":"Poos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Thalheimer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Griesinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian","family":"Kron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,24]]},"reference":[{"issue":"12","key":"803_CR1","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1007\/s00761-018-0480-2","volume":"24","author":"K Kraywinkel","year":"2018","unstructured":"Kraywinkel K, Sch\u00f6nfeld I. Epidemiologie des nichtkleinzelligen Lungenkarzinoms in Deutschland. Onkol. 2018;24(12):946\u201351.","journal-title":"Onkol"},{"key":"803_CR2","unstructured":"Koch-Institut R. Krebs in Deutschland f\u00fcr 2019\/2020. 2023 [cited 2025 July 4]; Available from: https:\/\/edoc.rki.de\/handle\/176904\/11438."},{"issue":"3","key":"803_CR3","first-page":"209","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71(3):209\u201349.","journal-title":"CA Cancer J Clin"},{"issue":"3","key":"803_CR4","first-page":"229","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229\u201363.","journal-title":"CA Cancer J Clin"},{"key":"803_CR5","unstructured":"Krebs - Kurzbeitr\u00e4ge - Kleinzellige und nicht-kleinzellige Lungenkarzinome: Aktualisierte Leitlinien bei Onkopedia [Internet]. [cited 2025 July 7]. Available from: https:\/\/www.krebsdaten.de\/Krebs\/DE\/Content\/Publikationen\/Kurzbeitraege\/Archiv2023\/2023_2_NSCLC_SCLC_Leitlinie.html."},{"issue":"3","key":"803_CR6","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1016\/j.lungcan.2015.10.007","volume":"90","author":"A Eberle","year":"2015","unstructured":"Eberle A, Jansen L, Castro F, Krilaviciute A, Luttmann S, Emrich K, et al. Lung cancer survival in Germany: A population-based analysis of 132,612 lung cancer patients. Lung Cancer. 2015;90(3):528\u201333.","journal-title":"Lung Cancer"},{"key":"803_CR7","doi-asserted-by":"crossref","unstructured":"Frost N, Griesinger F, Hoffmann H, L\u00e4nger F, Nestle U, Sch\u00fctte W, et al. Lung Cancer in Germany. J Thorac Oncol. 2022 June 1;17(6):742\u201350.","DOI":"10.1016\/j.jtho.2022.03.010"},{"key":"803_CR8","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1016\/j.lungcan.2020.10.012","volume":"152","author":"F Griesinger","year":"2021","unstructured":"Griesinger F, Eberhardt W, Nusch A, Reiser M, Zahn MO, Maintz C, et al. Biomarker testing in non-small cell lung cancer in routine care: Analysis of the first 3,717 patients in the German prospective, observational, nation-wide CRISP Registry (AIO-TRK-0315). Lung Cancer. 2021;152:174\u201384.","journal-title":"Lung Cancer"},{"issue":"4","key":"803_CR9","doi-asserted-by":"publisher","first-page":"505","DOI":"10.2217\/fon-2021-1040","volume":"18","author":"Y Zheng","year":"2022","unstructured":"Zheng Y, Vioix H, Liu FX, Singh B, Sharma S, Sharda D. Diagnostic and Economic Value of Biomarker Testing for Targetable Mutations in Non-Small-Cell Lung Cancer: a Literature Review. Future Oncol. 2022;18(4):505\u201318.","journal-title":"Future Oncol"},{"key":"803_CR10","doi-asserted-by":"publisher","first-page":"100839","DOI":"10.1016\/j.lanepe.2024.100839","volume":"38","author":"VD De Jager","year":"2024","unstructured":"De Jager VD, Timens W, Bayle A, Botling J, Brcic L, B\u00fcttner R, et al. Future perspective for the application of predictive biomarker testing in advanced stage non-small cell lung cancer. Lancet Reg Health - Eur. 2024;38:100839.","journal-title":"Lancet Reg Health - Eur"},{"issue":"10026","key":"803_CR11","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1016\/S0140-6736(16)00004-0","volume":"387","author":"F Barlesi","year":"2016","unstructured":"Barlesi F, Mazieres J, Merlio JP, Debieuvre D, Mosser J, Lena H, et al. Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT). Lancet Lond Engl. 2016;387(10026):1415\u201326.","journal-title":"Lancet Lond Engl"},{"key":"803_CR12","doi-asserted-by":"publisher","unstructured":"Jing C, Mao X, Wang Z, Sun K, Ma R, Wu J, et al. Next\u2013generation sequencing\u2013based detection of EGFR, KRAS, BRAF, NRAS, PIK3CA, Her\u20132 and TP53 mutations in patients with non\u2013small cell lung cancer. Mol Med Rep [Internet]. 2018 June 22 [cited 2025 July 4]; Available from: http:\/\/www.spandidos-publications.com\/https:\/\/doi.org\/10.3892\/mmr.2018.9210.","DOI":"10.3892\/mmr.2018.9210"},{"key":"803_CR13","first-page":"Doc01","volume":"23","author":"M Vogeser","year":"2025","unstructured":"Vogeser M, Schumacher T, B\u00fchling F. Medical laboratory diagnostics in Germany \u2013 a status report 2024. GMS Ger Med Sci. 2025;23:Doc01.","journal-title":"GMS Ger Med Sci"},{"issue":"11","key":"803_CR14","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1136\/jclinpath-2014-202404","volume":"67","author":"IA Cree","year":"2014","unstructured":"Cree IA, Deans Z, Ligtenberg MJL, Normanno N, Edsj\u00f6 A, Rouleau E, et al. Guidance for laboratories performing molecular pathology for cancer patients. J Clin Pathol. 2014;67(11):923\u201331.","journal-title":"J Clin Pathol"},{"key":"803_CR15","unstructured":"K\u00e4stner A, Kron A, van den Berg N, Moon K, Scheffler M, Schillinger G, et al. Evaluation of the effectiveness of a nationwide precision medicine program for patients with advanced non-small cell lung cancer in Germany: a historical cohort analysis. Lancet Reg Health \u2013 Eur [Internet]. 2024 Jan 1 [cited 2025 Sept 25];36. Available from: https:\/\/www.thelancet.com\/journals\/lanepe\/article\/PIIS2666-7762(23)00207-7\/fulltext."},{"key":"803_CR16","unstructured":"Weber V, Wolff LL, Thalheimer M, Fink L, Griesinger F, Mocek A. Herausforderungen und Handlungsopti onen bei der molekularen Diagnosti k des nicht-kleinzelligen Lungenkrebs in Deutschland - Diskussionsimpulse f\u00fcr die Umsetzung einer Reflextestung [Internet]. IGES Institut; 2024 July [cited 2025 Apr 23]. Available from: https:\/\/www.iges.com\/sites\/igesgroup\/iges.de\/myzms\/content\/e6\/e1621\/e10211\/e59145\/e75251\/e75252\/e75254\/attr_objs75256\/IGES_Lungenkrebs_Whitepaper_2024_ger.pdf?preview=preview&utm_source=chatgpt.com."},{"key":"803_CR17","unstructured":"Loges PD med, D rer nat B, Ostermann UPD. med H. Umfrage zu Testbereitschaft beim NSCLC in Deutschland [Internet]. 2024 [cited 2025 July 4]. Available from: https:\/\/www.journalonko.de\/thorakale-tumoren\/nsclc\/umfrage-testbereitschaft-nsclc-deutschland."},{"issue":"7\u20138","key":"803_CR18","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1007\/s00508-024-02351-3","volume":"137","author":"A Lang-St\u00f6berl","year":"2025","unstructured":"Lang-St\u00f6berl A, Fabikan H, Hochmair M, Kirchbacher K, Rodriguez VM, Ay L, et al. The Landsteiner lung cancer research platform (LALUCA) : Objectives, methodology and implementation of a real-world clinical lung cancer registry. Wien Klin Wochenschr. 2025;137(7\u20138):197\u2013204.","journal-title":"Wien Klin Wochenschr"},{"key":"803_CR19","unstructured":"LALUCA [Internet]. [cited 2025 Nov 6]. LALUCA - Longitudinal Analysis of Lung Cancer Data. Available from: https:\/\/www.laluca.at."},{"key":"803_CR20","doi-asserted-by":"crossref","unstructured":"Griesinger F, Eberhardt WEE, Hoffknecht P, Metzenmacher M, Wehler T, Kokowski K, et al. 1364P Treatment and outcome of a real-world cohort of patients with advanced, non-squamous NSCLC and KRAS mutations with a special focus on KRAS G12C. Ann Oncol. 2020 Sept;131:S872.","DOI":"10.1016\/j.annonc.2020.08.1678"},{"issue":"4","key":"803_CR21","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1016\/j.jtho.2018.12.013","volume":"14","author":"M Scheffler","year":"2019","unstructured":"Scheffler M, Ihle MA, Hein R, Merkelbach-Bruse S, Scheel AH, Siemanowski J, et al. K-ras Mutation Subtypes in NSCLC and Associated Co-occuring Mutations in Other Oncogenic Pathways. J Thorac Oncol. 2019;14(4):606\u201316.","journal-title":"J Thorac Oncol"},{"key":"803_CR22","doi-asserted-by":"crossref","unstructured":"Aggarwal S, Whipple S, Hsu H, Tu H, Carrigan G, Wang X, et al. 1339P Clinicopathological characteristics and treatment patterns observed in real-world care in patients with advanced non-small cell lung cancer (NSCLC) and KRAS G12C mutations in the Flatiron Health (FH)-Foundation Medicine (FMI) Clinico-Genomic Database (CGDB). Ann Oncol. 2020 Sept;1:31:S860.","DOI":"10.1016\/j.annonc.2020.08.1653"},{"key":"803_CR23","unstructured":"heiser. Deutlich bessere \u00dcberlebensraten f\u00fcr Lungenkrebs-Erkrankte im nationalen Netzwerk Genomische Medizin [Internet]. Monitor Versorgungsforschung. 2023 [cited 2025 Nov 6]. Available from: https:\/\/www.monitor-versorgungsforschung.de\/en\/news\/deutlich-bessere-ueberlebensraten-fuer-lungenkrebs-erkrankte-im-nationalen-netzwerk-genomische-medizin\/."},{"issue":"1","key":"803_CR24","doi-asserted-by":"publisher","first-page":"e000147","DOI":"10.1136\/jitc-2019-000147","volume":"8","author":"DM Merino","year":"2020","unstructured":"Merino DM, McShane LM, Fabrizio D, Funari V, Chen SJ, White JR, et al. Establishing guidelines to harmonize tumor mutational burden (TMB): in silico assessment of variation in TMB quantification across diagnostic platforms: phase I of the Friends of Cancer Research TMB Harmonization Project. J Immunother Cancer. 2020;8(1):e000147.","journal-title":"J Immunother Cancer"},{"key":"803_CR25","doi-asserted-by":"crossref","unstructured":"Mosele MF, Westphalen CB, Stenzinger A, Barlesi F, Bayle A, Bi\u00e8che I, et al. Recommendations for the use of next-generation sequencing (NGS) for patients with advanced cancer in 2024: a report from the ESMO Precision Medicine Working Group. Ann Oncol. 2024 July 1;35(7):588\u2013606.","DOI":"10.1016\/j.annonc.2024.04.005"},{"key":"803_CR26","doi-asserted-by":"publisher","first-page":"e2200546","DOI":"10.1200\/PO.22.00546","volume":"7","author":"E Arriola","year":"2023","unstructured":"Arriola E, Bernab\u00e9 R, Campelo RG, Biscuola M, Enguita AB, L\u00f3pez-R\u00edos F, et al. Cost-Effectiveness of Next-Generation Sequencing Versus Single-Gene Testing for the Molecular Diagnosis of Patients With Metastatic Non-Small-Cell Lung Cancer From the Perspective of Spanish Reference Centers. JCO Precis Oncol. 2023;7:e2200546.","journal-title":"JCO Precis Oncol"},{"issue":"2","key":"803_CR27","doi-asserted-by":"publisher","first-page":"e70018","DOI":"10.1002\/2056-4538.70018","volume":"11","author":"U Malapelle","year":"2025","unstructured":"Malapelle U, Chen CC, de \u00c1lava E, Hofman P, Kazdal D, Kim TJ, et al. Costs of biomarker testing in advanced non-small cell lung cancer: a global study comparing next-generation sequencing and single-gene testing. J Pathol Clin Res. 2025;11(2):e70018.","journal-title":"J Pathol Clin Res"},{"issue":"11","key":"803_CR28","doi-asserted-by":"publisher","first-page":"4221","DOI":"10.21037\/tlcr-21-570","volume":"10","author":"M Zacharias","year":"2021","unstructured":"Zacharias M, Absenger G, Kashofer K, Wurm R, Lindenmann J, Terbuch A, et al. Reflex testing in non-small cell lung carcinoma using DNA- and RNA-based next-generation sequencing\u2014a single-center experience. Transl Lung Cancer Res. 2021;10(11):4221\u201334.","journal-title":"Transl Lung Cancer Res"},{"issue":"5","key":"803_CR29","doi-asserted-by":"publisher","first-page":"903","DOI":"10.3390\/cancers16050903","volume":"16","author":"M Zacharias","year":"2024","unstructured":"Zacharias M, Konjic S, Kratochwill N, Absenger G, Terbuch A, Jost PJ, et al. Expanding Broad Molecular Reflex Testing in Non-Small Cell Lung Cancer to Squamous Histology. Cancers. 2024;16(5):903.","journal-title":"Cancers"},{"key":"803_CR30","unstructured":"Krebs. - Datenbankabfrage [Internet]. [cited 2025 July 4]. Available from: https:\/\/www.krebsdaten.de\/Krebs\/DE\/Datenbankabfrage\/datenbankabfrage_stufe1_node.html."},{"key":"803_CR31","unstructured":"Vorausberechneter, Bev\u00f6lkerungsstand. Deutschland, Stichtag, Varianten der Bev\u00f6lkerungsvorausberechnung, Geschlecht, Altersjahre [Internet]. [cited 2025 July 4]. Available from: https:\/\/www-genesis.destatis.de\/datenbank\/online\/statistic\/12421\/table\/12421-0002\/table-toolbar."},{"key":"803_CR32","unstructured":"Daten zum Gesundheitswesen. Versicherte [Internet]. [cited 2025 July 4]. Available from: https:\/\/www.vdek.com\/presse\/daten\/b_versicherte.html."},{"key":"803_CR33","unstructured":"Langer T, Pr\u00e4vention. Diagnostik, Therapie und Nachsorge des Lungenkarzinoms. 2025."},{"issue":"11","key":"803_CR34","doi-asserted-by":"publisher","first-page":"S2237","DOI":"10.1016\/j.jtho.2017.09.1529","volume":"12","author":"F Griesinger","year":"2017","unstructured":"Griesinger F, Eberhardt W, Nusch A, Reiser M, Losem C, Ketzler-Henkel S, et al. P3.01-088 Molecular Testing and First-Line Treatment of Patients with NSCLC. First Results from the German CRISP Study (AIO-TRK-0315). J Thorac Oncol. 2017;12(11):S2237.","journal-title":"J Thorac Oncol"},{"issue":"1","key":"803_CR35","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.jtho.2015.09.009","volume":"11","author":"P Goldstraw","year":"2016","unstructured":"Goldstraw P, Chansky K, Crowley J, Rami-Porta R, Asamura H, Eberhardt WEE, et al. The IASLC Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Lung Cancer. J Thorac Oncol. 2016;11(1):39\u201351.","journal-title":"J Thorac Oncol"},{"key":"803_CR36","unstructured":"Tumorspezifische Auswertungen des Tumorregister. M\u00fcnchen am Tumorzentrum M\u00fcnchen [Internet]. [cited 2025 July 4]. Available from: https:\/\/www.tumorregister-muenchen.de\/facts\/specific_analysis.php."},{"issue":"4","key":"803_CR37","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1007\/s00428-017-2268-y","volume":"472","author":"C Schwegler","year":"2018","unstructured":"Schwegler C, Kaufmann D, Pfeiffer D, Aebi S, Diebold J, Gautschi O. Population-level effect of molecular testing and targeted therapy in patients with advanced pulmonary adenocarcinoma: a prospective cohort study. Virchows Arch Int J Pathol. 2018;472(4):581\u20138.","journal-title":"Virchows Arch Int J Pathol"},{"key":"803_CR38","doi-asserted-by":"crossref","unstructured":"Schrock AB, Frampton GM, Suh J, Chalmers ZR, Rosenzweig M, Erlich RL, et al. Characterization of 298 Patients with Lung Cancer Harboring MET Exon 14 Skipping Alterations. J Thorac Oncol Off Publ Int Assoc Study Lung Cancer. 2016 Sept;11(9):1493\u2013502.","DOI":"10.1016\/j.jtho.2016.06.004"},{"key":"803_CR39","unstructured":"Calgaro A. Accelerated approval for drug targeting NRG1 [Internet]. Lung Cancer Research Foundation. 2025 [cited 2025 July 4]. Available from: https:\/\/www.lungcancerresearchfoundation.org\/accelerated-approval-for-drug-targeting-nrg1\/."},{"issue":"8","key":"803_CR40","first-page":"e107","volume":"12","author":"ND Gay","year":"2017","unstructured":"Gay ND, Wang Y, Beadling C, Warrick A, Neff T, Corless CL, et al. Durable Response to Afatinib in Lung Adenocarcinoma Harboring NRG1 Gene Fusions. J Thorac Oncol Off Publ Int Assoc Study Lung Cancer. 2017;12(8):e107\u201310.","journal-title":"J Thorac Oncol Off Publ Int Assoc Study Lung Cancer"},{"issue":"16","key":"803_CR41","doi-asserted-by":"publisher","first-page":"4966","DOI":"10.1158\/1078-0432.CCR-19-0160","volume":"25","author":"S Jonna","year":"2019","unstructured":"Jonna S, Feldman RA, Swensen J, Gatalica Z, Korn WM, Borghaei H, et al. Detection of NRG1 Gene Fusions in Solid Tumors. Clin Cancer Res Off J Am Assoc Cancer Res. 2019;25(16):4966\u201372.","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"issue":"3","key":"803_CR42","doi-asserted-by":"publisher","first-page":"188707","DOI":"10.1016\/j.bbcan.2022.188707","volume":"1877","author":"C Zhang","year":"2022","unstructured":"Zhang C, Mei W, Zeng C. Oncogenic Neuregulin 1 gene (NRG1) fusions in cancer: A potential new therapeutic opportunities. Biochim Biophys Acta Rev Cancer. 2022;1877(3):188707.","journal-title":"Biochim Biophys Acta Rev Cancer"},{"key":"803_CR43","doi-asserted-by":"crossref","unstructured":"Stransky N, Cerami E, Schalm S, Kim JL, Lengauer C. The landscape of kinase fusions in cancer. Nat Commun. 2014 Sept 10;5(1):4846.","DOI":"10.1038\/ncomms5846"},{"key":"803_CR44","doi-asserted-by":"crossref","unstructured":"Brahmer J, Reckamp KL, Baas P, Crin\u00f2 L, Eberhardt WEE, Poddubskaya E, et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med. 2015 July;9(2):123\u201335.","DOI":"10.1056\/NEJMoa1504627"},{"issue":"17","key":"803_CR45","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1056\/NEJMoa1507643","volume":"373","author":"H Borghaei","year":"2015","unstructured":"Borghaei H, Paz-Ares L, Horn L, Spigel DR, Steins M, Ready NE, et al. Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. N Engl J Med. 2015;373(17):1627\u201339.","journal-title":"N Engl J Med"},{"issue":"21","key":"803_CR46","doi-asserted-by":"publisher","first-page":"2018","DOI":"10.1056\/NEJMoa1501824","volume":"372","author":"EB Garon","year":"2015","unstructured":"Garon EB, Rizvi NA, Hui R, Leighl N, Balmanoukian AS, Eder JP, et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med. 2015;372(21):2018\u201328.","journal-title":"N Engl J Med"},{"issue":"3","key":"803_CR47","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/S1470-2045(15)70054-9","volume":"16","author":"NA Rizvi","year":"2015","unstructured":"Rizvi NA, Mazi\u00e8res J, Planchard D, Stinchcombe TE, Dy GK, Antonia SJ, et al. Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial. Lancet Oncol. 2015;16(3):257\u201365.","journal-title":"Lancet Oncol"},{"issue":"10027","key":"803_CR48","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1016\/S0140-6736(15)01281-7","volume":"387","author":"RS Herbst","year":"2016","unstructured":"Herbst RS, Baas P, Kim DW, Felip E, P\u00e9rez-Gracia JL, Han JY, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet Lond Engl. 2016;387(10027):1540\u201350.","journal-title":"Lancet Lond Engl"},{"key":"803_CR49","doi-asserted-by":"publisher","unstructured":"Yang J, Pyo JS, Kang G. Clinicopathological significance and diagnostic approach of ROS1 rearrangement in non-small cell lung cancer: a meta-analysis: ROS1 in non-small cell lung cancer. Int J Biol Markers [Internet]. 2018 June 6 [cited 2025 Sept 30]; Available from: https:\/\/journals.sagepub.com\/doi\/https:\/\/doi.org\/10.1177\/1724600818772194.","DOI":"10.1177\/1724600818772194"},{"key":"803_CR50","doi-asserted-by":"publisher","unstructured":"Engelhardt M, Mertelsmann R, Justus D. Das Blaue Buch - Chemotherapie-Manual H\u00e4matologie und Onkologie [Internet]. 8th edn. Berlin, Germany: Springer; 2023. Available from: https:\/\/link.springer.com\/book\/https:\/\/doi.org\/10.1007\/978-3-662-67749-0.","DOI":"10.1007\/978-3-662-67749-0"},{"key":"803_CR51","doi-asserted-by":"crossref","unstructured":"Kurte MS, Siefen AC, Dengler R, Kron F. \u00d6konomische Analyse der molekularen Diagnostik beim nichtkleinzelligen Lungenkarzinom \u2013 Eine Bestandsaufnahme der Versorgungs- und Verg\u00fctungssituation in der deutschen Krankenhauslandschaft. Gesundheits\u00f6konomie Qual 2023 July 13;29:171\u20139.","DOI":"10.1055\/a-2097-1375"},{"issue":"3","key":"803_CR52","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1007\/s00292-022-01066-4","volume":"43","author":"L Brcic","year":"2022","unstructured":"Brcic L, Savic Prince S. Pr\u00e4diktive Immunzytochemie beim nicht-kleinzelligen Lungenkarzinom. Pathol. 2022;43(3):222\u20138.","journal-title":"Pathol"},{"issue":"1","key":"803_CR53","doi-asserted-by":"publisher","first-page":"21168","DOI":"10.1038\/s41598-023-48613-4","volume":"13","author":"R de Oliveira Cavagna","year":"2023","unstructured":"de Oliveira Cavagna R, de Andrade ES, Tadin Reis M, de Paula FE, Noriz Berardinelli G, Bonatelli M, et al. Detection of NTRK fusions by RNA-based nCounter is a feasible diagnostic methodology in a real-world scenario for non-small cell lung cancer assessment. Sci Rep. 2023;13(1):21168.","journal-title":"Sci Rep"},{"key":"803_CR54","unstructured":"Institut f\u00fcr Qualit\u00e4t und Wirtschaftlichkeit im Gesundheitswesen (IQWiG). Allgemeine Methoden. Version 7.0 vom 19.09.2023. K\u00f6ln: IQWiG. 2023. Available from: https:\/\/www.iqwig.de\/methoden\/allgemeine-methoden_version-7-0.pdf."},{"key":"803_CR55","doi-asserted-by":"crossref","unstructured":"Silas U, Bl\u00fcher M, Smith A, Saunders R. Fast in-house next-generation sequencing in the diagnosis of metastatic non-small cell lung cancer: a hospital budget impact analysis. J Health Econ Outcomes Res. 2023 June 26;10.","DOI":"10.36469\/001c.77686"},{"issue":"2","key":"803_CR56","doi-asserted-by":"publisher","first-page":"2348","DOI":"10.3390\/curroncol30020180","volume":"30","author":"BS Sheffield","year":"2023","unstructured":"Sheffield BS, Eaton K, Emond B, Lafeuille MH, Hilts A, Lefebvre P, et al. Cost Savings of Expedited Care with Upfront Next-Generation Sequencing Testing versus Single-Gene Testing among Patients with Metastatic Non-Small Cell Lung Cancer Based on Current Canadian Practices. Curr Oncol. 2023;30(2):2348\u201365.","journal-title":"Curr Oncol"},{"issue":"10, Supplement","key":"803_CR57","doi-asserted-by":"publisher","first-page":"S290","DOI":"10.1016\/j.jtho.2024.09.523","volume":"19","author":"J Rose","year":"2024","unstructured":"Rose J, Gosula V, Cho S, Sadri N, Yoest J, Donner A, et al. P2.17A.04 Cost Effectiveness of a System-Level Precision Medicine Intervention for Stage IV Non-Small Cell Lung Cancer Patients. J Thorac Oncol. 2024;19(10, Supplement):S290.","journal-title":"J Thorac Oncol"},{"key":"803_CR58","doi-asserted-by":"crossref","unstructured":"Ortendahl JD, Cuyun Carter G, Thakkar SG, Bognar K, Hall DW, Abdou Y, et al. Costs and benefits of whole-exome, whole-transcriptome sequencing in patients with advanced non\u2013small cell lung cancer. JCO Precis Oncol. 2025 June;17:9:e2400640.","DOI":"10.1200\/PO-24-00640"},{"key":"803_CR59","doi-asserted-by":"crossref","unstructured":"Auber R, Shiller M. PP01.134 pathologist driven reflex testing provides rapid, orthogonal results to NSCLC patients in response to comprehensive genomic profiling QNS. J Thorac Oncol. 2024 July;19(7):e58.","DOI":"10.1016\/j.jtho.2024.05.357"},{"key":"803_CR60","unstructured":"Fallpauschalen-Katalog 2025, InEK GmbH [Internet]. [cited 2025 Nov 6]. Available from: https:\/\/www.g-drg.de\/ag-drg-system-2025\/fallpauschalen-katalog\/fallpauschalen-katalog-2025."},{"key":"803_CR61","unstructured":"Schumacher M et al. Bronchuskarzinom, Medizinische Leitlinie. Tumorzentrum Ober\u00f6sterreich. [cited 2025 Dec 12]. Available from: https:\/\/www.tumorzentrum.at\/fileadmin\/user_upload\/Leitlinien\/20230321_Leitlinie_Bronchuskarzinom.pdf."},{"issue":"1","key":"803_CR62","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1007\/s12254-019-00565-0","volume":"13","author":"HH Popper","year":"2020","unstructured":"Popper HH, Gruber-M\u00f6senbacher U, Pall G, M\u00fcllauer L, Hochmair M, Krenbek D, et al. The 2020 update of the recommendations of the Austrian working group on lung pathology and oncology for the diagnostic workup of non-small cell lung cancer with focus on predictive biomarkers. Memo - Mag Eur Med Oncol. 2020;13(1):11\u201326. https:\/\/doi.org\/10.1007\/s12254-019-00565-0.","journal-title":"Memo - Mag Eur Med Oncol"},{"key":"803_CR63","unstructured":"Satitisches Bundesamt (Destatis). Mikrozensus 2021 [Internet]. [cited 2026 Jan 12]. K\u00f6rpermasse nach Altersgruppen und Geschlecht. Available from: https:\/\/www.destatis.de\/DE\/Themen\/Gesellschaft-Umwelt\/Gesundheit\/Gesundheitszustand-Relevantes-Verhalten\/Tabellen\/liste-koerpermasse.html."},{"key":"803_CR64","unstructured":"IQWiG [Internet]. [cited 2026 Jan 27]. IQWiG presents a method for evaluating the relation between cost and benefit. Available from: https:\/\/www.iqwig.de\/en\/presse\/press-releases\/press-releases-detailpage_10917.html."},{"issue":"3","key":"803_CR65","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1007\/s00292-019-0605-4","volume":"40","author":"R B\u00fcttner","year":"2019","unstructured":"B\u00fcttner R, Wolf J, Kron A. Nationales Netzwerk Genomische Medizin. Das nationale Netzwerk Genomische Medizin (nNGM). Pathol. 2019;40(3):276\u201380. https:\/\/doi.org\/10.1007\/s00292-019-0605-4.","journal-title":"Pathol"},{"key":"803_CR66","unstructured":"\u00dcber das nNGM. nNGM [Internet]. [cited 2025 Nov 20]. Available from: https:\/\/nngm.de\/ueber-das-nngm\/."},{"key":"803_CR67","unstructured":"Gemeinsamer Bundesausschuss (G-BA). Generelle, alle ASV-Indikationen \u00fcbergreifende Evaluation und Weiterentwicklung der ASV-RL. Ergeb Gem\u00e4\u00df Nr 141 ANBest-IF. 2022."},{"key":"803_CR68","doi-asserted-by":"publisher","unstructured":"Dengler R, Kron F, Froschauer S. Die ambulante spezialfach\u00e4rztliche Versorgung (ASV) im Kontext der aktuellen gesundheitspolitischen Reformen. 2023 Oct 3. https:\/\/doi.org\/10.24945\/MVF.05.23.1866-0533.2548.","DOI":"10.24945\/MVF.05.23.1866-0533.2548"},{"key":"803_CR69","unstructured":"GKV-Spitzenverband. Modellvorhaben Genomsequenzierung nach \u00a7 64e SGB V [Internet]. GKV-Spitzenverband; [cited 2026 Jan 27]. Available from: https:\/\/www.gkv-spitzenverband.de\/krankenversicherung\/forschung_modellvorhaben\/mv_genomsequenzierung\/genomsequenzierung.jsp."},{"key":"803_CR70","doi-asserted-by":"publisher","first-page":"109451","DOI":"10.1016\/j.lungcan.2026.109451","volume":"217","author":"R Mudumba","year":"2026","unstructured":"Mudumba R, Liu X, Jin S, Davis IJ, Baid D, Romley JA, Nieva JJ. Comparative effectiveness of first-line targeted therapies in ALK-positive non-small cell lung cancer: real-world evidence of tyrosine kinase inhibitors. Lung Cancer. 2026;217:109451. https:\/\/doi.org\/10.1016\/j.lungcan.2026.109451.","journal-title":"Lung Cancer"},{"issue":"2","key":"803_CR71","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1056\/NEJMoa2304594","volume":"389","author":"M Tsuboi","year":"2023","unstructured":"Tsuboi M, Herbst RS, John T, Kato T, Majem M, Groh\u00e9 C, et al. Overall Survival with Osimertinib in Resected EGFR-Mutated NSCLC. N Engl J Med. 2023;389(2):137\u201347. https:\/\/doi.org\/10.1056\/NEJMoa2304594.","journal-title":"N Engl J Med"},{"issue":"14","key":"803_CR72","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1056\/NEJMoa2402737","volume":"390","author":"YL Wu","year":"2024","unstructured":"Wu YL, Dziadziuszko R, Ahn JS, Barlesi F, Nishio M, Lee SH, et al. Alectinib in Resected ALK-Positive Non-Small-Cell Lung Cancer. N Engl J Med. 2024;390(14):1265\u201376. https:\/\/doi.org\/10.1056\/NEJMoa2402737.","journal-title":"N Engl J Med"}],"container-title":["Cost Effectiveness and Resource Allocation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12962-026-00803-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12962-026-00803-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12962-026-00803-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T05:19:49Z","timestamp":1784870389000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12962-026-00803-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,24]]},"references-count":72,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["803"],"URL":"https:\/\/doi.org\/10.1186\/s12962-026-00803-3","relation":{},"ISSN":["1478-7547"],"issn-type":[{"value":"1478-7547","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,24]]},"assertion":[{"value":"21 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was funded by AstraZeneca GmbH.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"95"}}